TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR)

April 25, 2024 updated by: American Society of Clinical Oncology

Targeted Agent and Profiling Utilization Registry (TAPUR) Study

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug.

NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers).

********************************************************************

Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress.

********************************************************************

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the safety and efficacy of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic variant. TAPUR will study Food and Drug Administration (FDA)-approved targeted therapies that are contributed by collaborating pharmaceutical companies, catalogue the choice of molecular profiling test by clinical oncologists and develop hypotheses for additional clinical trials.

Study Type

Interventional

Enrollment (Estimated)

3791

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Pam Mangat, MS
  • Phone Number: www.tapur.org
  • Email: tapur@asco.org

Study Locations

  • United States
    • Alabama
      • Birmingham, Alabama, United States, 35294
        • Recruiting
        • University of Alabama at Birmingham Comprehensive Cancer Center
        • Principal Investigator:
          • Mehmet Akce, MD
        • Contact:
    • Arizona
      • Phoenix, Arizona, United States, 85338
        • Recruiting
        • Cancer Treatment Centers of America-Phoenix
        • Contact:
        • Principal Investigator:
          • Sagun Shrestha, MD
    • California
      • Auburn, California, United States, 95602
        • Recruiting
        • Sutter Auburn
        • Contact:
        • Principal Investigator:
          • Deepti Behl, MD
      • Berkeley, California, United States, 94705
      • Los Angeles, California, United States, 90025
        • Recruiting
        • The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate
        • Contact:
        • Principal Investigator:
          • Omid Hamid, MD
      • Oakland, California, United States, 94611
        • Recruiting
        • Kaiser Permanente - Oakland Medical Center
        • Contact:
        • Principal Investigator:
          • Jennifer M Suga, MD
      • Palo Alto, California, United States, 94301
      • Roseville, California, United States, 95661
        • Recruiting
        • Kaiser Permanente - Roseville Medical Center
        • Contact:
        • Principal Investigator:
          • Jennifer M Suga, MD
      • Roseville, California, United States, 95661
        • Recruiting
        • Sutter Roseville
        • Contact:
        • Principal Investigator:
          • Deepti Behl, MD
      • Sacramento, California, United States, 95814
        • Recruiting
        • Kaiser Permanente - Sacramento Medical Center
        • Contact:
        • Principal Investigator:
          • Jennifer M Suga, MD
      • Sacramento, California, United States, 95816
        • Recruiting
        • Sutter Sacramento
        • Principal Investigator:
          • Deepti Behl, MD
        • Contact:
      • San Francisco, California, United States, 94115
        • Recruiting
        • California Pacific Medical Center Research Institute
        • Contact:
        • Principal Investigator:
          • Deepti Behl, MD
      • San Francisco, California, United States, 94080
        • Recruiting
        • Kaiser Permanente - South San Francisco Medical Center
        • Contact:
        • Principal Investigator:
          • Jennifer M Suga, MD
      • San Francisco, California, United States, 94115
        • Recruiting
        • Kaiser Permanente - San Francisco Medical Center
        • Contact:
        • Principal Investigator:
          • Jennifer M Suga, MD
      • San Francisco, California, United States, 94115
        • Recruiting
        • Sutter Cancer Research Consortium
        • Contact:
        • Principal Investigator:
          • Stacy D'Andre, MD
      • San Jose, California, United States, 95119
        • Recruiting
        • Kaiser Permanente - San Jose Medical Center
        • Contact:
        • Principal Investigator:
          • Jennifer M Suga, MD
      • San Leandro, California, United States, 94577
        • Recruiting
        • Kaiser Permanente - San Leandro Medical Center
        • Contact:
        • Principal Investigator:
          • Jennifer M Suga, MD
      • Santa Clara, California, United States, 95051
        • Recruiting
        • Kaiser Permanente - Santa Clara Medical Center
        • Contact:
        • Principal Investigator:
          • Jennifer M Suga, MD
      • Santa Cruz, California, United States, 95065
      • Santa Cruz, California, United States, 994538
      • Sunnyvale, California, United States, 94086
      • Vallejo, California, United States, 94589
        • Recruiting
        • Kaiser Permanente - Vallejo Medical Center
        • Contact:
        • Principal Investigator:
          • Jennifer M. Suga, MD
      • Walnut Creek, California, United States, 94596
        • Recruiting
        • Kaiser Permanente - Walnut Creek Medical Center
        • Contact:
        • Principal Investigator:
          • Jennifer M Suga, MD
    • Connecticut
      • Bridgeport, Connecticut, United States, 06606
      • Hartford, Connecticut, United States, 06102
      • Meriden, Connecticut, United States, 06451
      • New Britain, Connecticut, United States, 06053
        • Recruiting
        • The Hospital of Central Connecticut (HOCC) Cancer Center
        • Contact:
        • Principal Investigator:
          • Wylie Hosmer, MD
      • Norwich, Connecticut, United States, 06360
      • Torrington, Connecticut, United States, 06790
      • Willimantic, Connecticut, United States, 06226
    • Florida
      • Altamonte Springs, Florida, United States, 32701
        • Recruiting
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
        • Contact:
        • Principal Investigator:
          • David Wright, MD
      • Bonita Springs, Florida, United States, 34135
        • Recruiting
        • Florida Cancer Specialists South / Sarah Cannon Research Institute
        • Contact:
        • Principal Investigator:
          • Fadi Kayali, MD
      • Bradenton, Florida, United States, 34211
        • Recruiting
        • Florida Cancer Specialists South / Sarah Cannon Research Institute
        • Contact:
        • Principal Investigator:
          • Fadi Kayali, MD
      • Brandon, Florida, United States, 33511
        • Recruiting
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
        • Contact:
        • Principal Investigator:
          • David Wright, MD
      • Cape Coral, Florida, United States, 33909
        • Recruiting
        • Florida Cancer Specialists South / Sarah Cannon Research Institute
        • Contact:
        • Principal Investigator:
          • Fadi Kayali, MD
      • Clearwater, Florida, United States, 33761
        • Recruiting
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
        • Contact:
        • Principal Investigator:
          • David Wright, MD
      • Daytona Beach, Florida, United States, 32117
        • Recruiting
        • Florida Cancer Specialists East / Sarah Cannon Research Institute
        • Contact:
        • Principal Investigator:
          • Schachar Peles, MD
      • Fleming Island, Florida, United States, 32003
        • Recruiting
        • Florida Cancer Specialists Panhandle / Sarah Cannon Research Institute
        • Contact:
        • Principal Investigator:
          • Viralkumar Bhanderi, MD
      • Fort Lauderdale, Florida, United States, 33308
      • Fort Myers, Florida, United States, 33901
        • Recruiting
        • Florida Cancer Specialists South / Sarah Cannon Research Institute
        • Contact:
        • Principal Investigator:
          • Fadi Kayali, MD
      • Fort Myers, Florida, United States, 33905
        • Recruiting
        • Florida Cancer Specialists South / Sarah Cannon Research Institute
        • Principal Investigator:
          • Fadi Kayali, MD
        • Contact:
      • Fort Myers, Florida, United States, 33908
        • Recruiting
        • Florida Cancer Specialists South / Sarah Cannon Research Institute
        • Contact:
        • Principal Investigator:
          • Fadi Kayali, MD
      • Gainesville, Florida, United States, 32610
        • Recruiting
        • University of Florida Health
        • Principal Investigator:
          • Thomas George, MD
        • Contact:
      • Gainesville, Florida, United States, 32605
        • Recruiting
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
        • Contact:
        • Principal Investigator:
          • David Wright, MD
      • Largo, Florida, United States, 33770
        • Recruiting
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
        • Contact:
        • Principal Investigator:
          • David Wright, MD
      • Lecanto, Florida, United States, 34461
        • Recruiting
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
        • Contact:
        • Principal Investigator:
          • David Wright, MD
      • Miami, Florida, United States, 33136
        • Recruiting
        • University of Miami Sylvester Comprehensive Cancer Center
        • Contact:
        • Principal Investigator:
          • Carmen Calfa, MD
      • Naples, Florida, United States, 34102
        • Recruiting
        • Florida Cancer Specialists South / Sarah Cannon Research Institute
        • Contact:
        • Principal Investigator:
          • Fadi Kayali, MD
      • Ocala, Florida, United States, 34474
        • Recruiting
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
        • Contact:
        • Principal Investigator:
          • David Wright, MD
      • Orange City, Florida, United States, 32763
        • Recruiting
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
        • Contact:
        • Principal Investigator:
          • David Wright, MD
      • Orlando, Florida, United States, 32806
        • Recruiting
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
        • Contact:
        • Principal Investigator:
          • David Wright, MD
      • Port Charlotte, Florida, United States, 33980
        • Recruiting
        • Florida Cancer Specialists South / Sarah Cannon Research Institute
        • Contact:
        • Principal Investigator:
          • Fadi Kayali, MD
      • Saint Petersburg, Florida, United States, 33705
        • Recruiting
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
        • Contact:
        • Principal Investigator:
          • David Wright, MD
      • Sarasota, Florida, United States, 34232
        • Recruiting
        • Florida Cancer Specialists South / Sarah Cannon Research Institute
        • Contact:
        • Principal Investigator:
          • Fadi Kayali, MD
      • Sarasota, Florida, United States, 34236
        • Recruiting
        • Florida Cancer Specialists South / Sarah Cannon Research Institute
        • Contact:
        • Principal Investigator:
          • Fadi Kayali, MD
      • Stuart, Florida, United States, 34994
        • Recruiting
        • Florida Cancer Specialists East / Sarah Cannon Research Institute
        • Contact:
        • Principal Investigator:
          • Schachar Peles, MD
      • Tallahassee, Florida, United States, 32308
        • Recruiting
        • Florida Cancer Specialists Panhandle / Sarah Cannon Research Institute
        • Contact:
        • Principal Investigator:
          • Viralkumar Bhanderi, MD
      • Tampa, Florida, United States, 33607
        • Recruiting
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
        • Contact:
        • Principal Investigator:
          • David Wright, MD
      • Tavares, Florida, United States, 32778
        • Recruiting
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
        • Contact:
        • Principal Investigator:
          • David Wright, MD
      • The Villages, Florida, United States, 32159
        • Recruiting
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
        • Contact:
        • Principal Investigator:
          • David Wright, MD
      • Trinity, Florida, United States, 34655
        • Recruiting
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
        • Contact:
        • Principal Investigator:
          • David Wright, MD
      • Venice, Florida, United States, 34285
        • Recruiting
        • Florida Cancer Specialists South / Sarah Cannon Research Institute
        • Contact:
        • Principal Investigator:
          • Fadi Kayali, MD
      • Venice, Florida, United States, 34292
        • Recruiting
        • Florida Cancer Specialists South / Sarah Cannon Research Institute
        • Contact:
        • Principal Investigator:
          • Fadi Kayali, MD
      • Vero Beach, Florida, United States, 32960
        • Recruiting
        • Florida Cancer Specialists East / Sarah Cannon Research Institute
        • Contact:
        • Principal Investigator:
          • Schachar Peles, MD
      • Wellington, Florida, United States, 33414
        • Recruiting
        • Florida Cancer Specialists East / Sarah Cannon Research Institute
        • Contact:
        • Principal Investigator:
          • Schachar Peles, MD
      • West Palm Beach, Florida, United States, 33401
        • Recruiting
        • Florida Cancer Specialists East / Sarah Cannon Research Institute
        • Principal Investigator:
          • Shachar Peles, MD
        • Contact:
      • Winter Park, Florida, United States, 32789
        • Recruiting
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
        • Contact:
        • Principal Investigator:
          • David Wright, MD
    • Georgia
      • Atlanta, Georgia, United States, 30322
        • Recruiting
        • Emory University Winship Cancer Institute
        • Contact:
        • Principal Investigator:
          • Olatunji Alese, MD
      • Atlanta, Georgia, United States, 30265
        • Recruiting
        • Cancer Treatment Centers of America - Atlanta
        • Contact:
        • Principal Investigator:
          • Bamidele Adesunloye, MD
      • Savannah, Georgia, United States, 31405
        • Recruiting
        • Summit Cancer Care
        • Contact:
        • Principal Investigator:
          • Mark Taylor, MD
      • Savannah, Georgia, United States, 31405
        • Recruiting
        • Gynecologic Oncology and Surgical Specialists at the Lewis Cancer & Research Pavilion
        • Contact:
        • Principal Investigator:
          • Mark Taylor, MD
      • Savannah, Georgia, United States, 31405
        • Recruiting
        • Lewis Cancer & Research Pavilion at the Melanoma, Skin Cancer & Sarcoma Institute
        • Contact:
        • Principal Investigator:
          • Mark Taylor, MD
      • Savannah, Georgia, United States, 31405
        • Recruiting
        • Lewis Cancer & Research Pavilion
        • Contact:
        • Principal Investigator:
          • Mark Taylor, MD
    • Hawaii
      • Honolulu, Hawaii, United States, 96813
        • Active, not recruiting
        • The Queen's Medical Center (The University of Texas MD Anderson Cancer Center)
    • Illinois
      • Chicago, Illinois, United States, 60099
        • Recruiting
        • Cancer Treatment Centers of America-Chicago
        • Contact:
        • Principal Investigator:
          • Evan Pisick, MD
    • Indiana
      • Indianapolis, Indiana, United States, 46250
        • Recruiting
        • Community Health Network (The University of Texas MD Anderson Cancer Center)
        • Contact:
        • Principal Investigator:
          • Funda Meric-Bernstam, MD
    • Maine
      • Augusta, Maine, United States, 04330
        • Recruiting
        • Harold Alfond Center for Cancer Care
        • Contact:
        • Principal Investigator:
          • Lindsay Hathaway, MD
      • Augusta, Maine, United States, 04330
        • Recruiting
        • Jackson Laboratory - Maine Cancer Genomics Initiative
        • Contact:
        • Principal Investigator:
          • Jens Rueter, MD
      • Belfast, Maine, United States, 04915
        • Recruiting
        • Waldo County General Hospital
        • Contact:
          • Jen Dalton, MHA, BSN, RN
          • Phone Number: 207-294-8291
          • Email: JDalton@mmc.org
        • Principal Investigator:
          • Roger Inhorn, MD
      • Biddeford, Maine, United States, 04005
        • Recruiting
        • SMHC Cancer Care and Blood Disorders -Biddeford
        • Principal Investigator:
          • Roger Inhorn, MD
        • Contact:
      • Brewer, Maine, United States, 04412
        • Recruiting
        • Northern Light Cancer Care
        • Principal Investigator:
          • Sarah Sinclair, MD
        • Contact:
      • Brewer, Maine, United States, 04412
        • Recruiting
        • Raish Peavey Haskell Children's Cancer and Treatment Center
        • Principal Investigator:
          • Sarah Sinclair, MD
        • Contact:
      • Brunswick, Maine, United States, 04011
        • Recruiting
        • MaineHealth Cancer Care -Brunswick
        • Contact:
          • Jen Dalton, MHA, BSN, RN
          • Phone Number: 207-294-8291
          • Email: JDalton@mmc.org
        • Principal Investigator:
          • Roger Inhorn, MD
      • Kennebunk, Maine, United States, 04043
        • Recruiting
        • New England Cancer Specialist
        • Contact:
        • Principal Investigator:
          • Christian Thomas, MD
      • Kittery, Maine, United States, 03904
        • Recruiting
        • York Hopsital Oncology & Infusion Care in Kittery
        • Contact:
        • Principal Investigator:
          • Marilyn McLaughlin, MD
      • Norway, Maine, United States, 04268
        • Recruiting
        • Stephens Memorial Hospital
        • Contact:
          • Jen Dalton, MHA, BSN, RN
          • Phone Number: 207-294-8291
          • Email: JDalton@mmc.org
        • Principal Investigator:
          • Roger Inhorn, MD
      • Rockport, Maine, United States, 04856
        • Recruiting
        • Penobscot Bay Medical Center
        • Contact:
          • Jen Dalton, MHA, BSN, RN
          • Phone Number: 207-294-8291
          • Email: JDalton@mmc.org
        • Principal Investigator:
          • Roger Inhorn, MD
      • Sanford, Maine, United States, 04073
        • Recruiting
        • SMHC Cancer Care and Blood Disorders -Sandford
        • Contact:
          • Jen Dalton, MHA, BSN, RN
          • Phone Number: 207-294-8291
          • Email: JDalton@mmc.org
        • Principal Investigator:
          • Roger Inhorn, MD
      • Scarborough, Maine, United States, 04074
        • Recruiting
        • Maine Children's Cancer Program
        • Contact:
          • Jen Dalton, MHA, BSN, RN
          • Phone Number: 207-294-8291
          • Email: JDalton@mmc.org
        • Principal Investigator:
          • Roger Inhorn, MD
      • Scarborough, Maine, United States, 04074
        • Recruiting
        • Maine Medical Partner's Women's Health
        • Contact:
          • Jen Dalton, MHA, BSN, RN
          • Phone Number: 207-294-8291
          • Email: JDalton@mmc.org
        • Principal Investigator:
          • Roger Inhorn, MD
      • Scarborough, Maine, United States, 04074
        • Recruiting
        • New England Cancer Specialist
        • Principal Investigator:
          • Christian Thomas, MD
        • Contact:
      • South Portland, Maine, United States, 04106
        • Recruiting
        • MaineHealth Cancer Care -South Portland
        • Contact:
          • Jen Dalton, MHA, BSN, RN
          • Phone Number: 207-294-8291
          • Email: JDalton@mmc.org
        • Principal Investigator:
          • Roger Inhorn, MD
      • Topsham, Maine, United States, 04086
        • Recruiting
        • New England Cancer Specialist
        • Principal Investigator:
          • Christian Thomas, MD
        • Contact:
      • Wells, Maine, United States, 04090
        • Recruiting
        • York Hospital Oncology & Infusion Care in Wells
        • Principal Investigator:
          • Marilyn McLaughlin, MD
        • Contact:
      • York, Maine, United States, 03909
        • Recruiting
        • York Hospital Oncology & Infusion Care in York
        • Contact:
        • Principal Investigator:
          • Marilyn McLaughlin, MD
    • Michigan
      • Ann Arbor, Michigan, United States, 48109
        • Recruiting
        • University of Michigan
        • Contact:
        • Principal Investigator:
          • Ajja Alva, MBBS
      • Ann Arbor, Michigan, United States, 48106
      • Detroit, Michigan, United States, 48236
      • Grand Blanc, Michigan, United States, 48439
      • Grand Rapids, Michigan, United States, 49503
        • Recruiting
        • Cancer Research Consortium of West Michigan
        • Contact:
        • Principal Investigator:
          • Kathleen J. Yost, MD
      • Lansing, Michigan, United States, 48912
      • Livonia, Michigan, United States, 48154
      • Pontiac, Michigan, United States, 48341
      • Saginaw, Michigan, United States, 48601
      • Traverse City, Michigan, United States, 48341
        • Recruiting
        • Michigan Cancer Research Consortium
        • Principal Investigator:
          • Philip Stella, MD
        • Contact:
        • Contact:
          • Phone Number: 877-590-5995
      • Warren, Michigan, United States, 48093
    • Nebraska
      • Omaha, Nebraska, United States, 68198
        • Recruiting
        • University of Nebraska Medical Center
        • Principal Investigator:
          • Alissa Marr, MD
        • Contact:
    • New Hampshire
      • Concord, New Hampshire, United States, 03103
        • Recruiting
        • NH Oncology - Hematology, PA
        • Principal Investigator:
          • Douglas Weckstein, MD
        • Contact:
      • Manchester, New Hampshire, United States, 03103
        • Recruiting
        • Solinsky Center for Cancer Care
        • Principal Investigator:
          • Douglas Weckstein, MD
        • Contact:
      • Portsmouth, New Hampshire, United States, 03801
        • Recruiting
        • New England Cancer Specialist
        • Principal Investigator:
          • Christian Thomas, MD
        • Contact:
    • New Mexico
      • Albuquerque, New Mexico, United States, 87110
        • Recruiting
        • Presbyterian Kaseman Hospital
        • Principal Investigator:
          • Bernard Tawfik, MD
        • Contact:
      • Albuquerque, New Mexico, United States, 87102
        • Recruiting
        • Lovelace Medical Center - Saint Joseph Square
        • Principal Investigator:
          • Bernard Tawfik, MD
        • Contact:
      • Albuquerque, New Mexico, United States, 87131
        • Recruiting
        • The University of New Mexico Comprehensive Cancer Center
        • Principal Investigator:
          • Bernard Tawfik, MD
        • Contact:
      • Las Cruces, New Mexico, United States, 88011
        • Recruiting
        • Memorial Medical Center
        • Principal Investigator:
          • Bernard Tawfik, MD
        • Contact:
      • Rio Rancho, New Mexico, United States, 87124
        • Recruiting
        • Presbyterian Rust Medical Center
        • Principal Investigator:
          • Bernard Tawfik, MD
        • Contact:
    • New York
      • Lake Success, New York, United States, 11042
        • Recruiting
        • Northwell Health Monter Cancer Center
        • Contact:
        • Principal Investigator:
          • Marina Frimer, MD
      • New Hyde Park, New York, United States, 11040
        • Recruiting
        • Cohen Children's Medical Center
        • Contact:
        • Principal Investigator:
          • Marina Frimer, MD
      • New York, New York, United States, 10032
        • Recruiting
        • Herbert Irving Comprehensive Cancer Center
        • Contact:
        • Principal Investigator:
          • Alexander Wei, MD
      • New York, New York, United States, 10065
        • Recruiting
        • Manhattan Eye, Ear, and Throat Hospital
        • Principal Investigator:
          • Marina Frimer, MD
        • Contact:
      • Sleepy Hollow, New York, United States, 10591
    • North Carolina
      • Chapel Hill, North Carolina, United States, 27599
        • Recruiting
        • Lineberger Comprehensive Cancer Center
        • Principal Investigator:
          • Shetal Patel, MD
        • Contact:
      • Charlotte, North Carolina, United States, 28277
        • Recruiting
        • Atrium Health's Levine Cancer Institute
        • Principal Investigator:
          • Kathryn F. Mileham, MD, FACP
        • Contact:
    • North Dakota
      • Bismarck, North Dakota, United States, 58501
        • Recruiting
        • Sanford Health- Bismarck
        • Contact:
        • Principal Investigator:
          • Peter Kurniali, MD
      • Fargo, North Dakota, United States, 58122
        • Recruiting
        • Sanford Health- Fargo
        • Contact:
        • Principal Investigator:
          • Anu Gaba, MD
    • Ohio
      • Cincinnati, Ohio, United States, 45219
        • Recruiting
        • University of Cincinnati Medical Center
        • Principal Investigator:
          • Trisha Wise-Draper, MD
        • Contact:
      • Kettering, Ohio, United States, 45429
      • West Chester, Ohio, United States, 45069
        • Recruiting
        • West Chester Hospital
        • Principal Investigator:
          • Trisha Wise-Draper, MD
        • Contact:
    • Oregon
      • Portland, Oregon, United States, 97213
        • Recruiting
        • Providence Health & Services
        • Contact:
        • Principal Investigator:
          • Evthokia Hobbs, MD
    • Pennsylvania
      • Allentown, Pennsylvania, United States, 18103
      • Bethlehem, Pennsylvania, United States, 18017
      • East Stroudsburg, Pennsylvania, United States, 18301
      • Hazleton, Pennsylvania, United States, 18201
      • Philadelphia, Pennsylvania, United States, 19111
        • Recruiting
        • Fox Chase Cancer Center
        • Principal Investigator:
          • Margaret von Mehren, MD
        • Contact:
    • South Carolina
      • Bluffton, South Carolina, United States, 29910
        • Recruiting
        • SC Cancer Specialists at St. Joseph's/Candler Bluffton
        • Contact:
        • Principal Investigator:
          • Mark Taylor, MD
      • Bluffton, South Carolina, United States, 29910
        • Recruiting
        • St. Joseph's/Candler Smith
        • Contact:
        • Principal Investigator:
          • Mark Taylor, MD
      • Bluffton, South Carolina, United States, 29910
        • Recruiting
        • Summit Cancer Care at St. Josph's/Candler Bluffton
        • Contact:
        • Principal Investigator:
          • Mark Taylor, MD
      • Hilton Head Island, South Carolina, United States, 29926
        • Recruiting
        • South Carolina Cancer Specialists
        • Contact:
        • Principal Investigator:
          • Mark Taylor, MD
    • South Dakota
      • Sioux Falls, South Dakota, United States, 57104
        • Recruiting
        • Sanford Cancer Center Oncology Clinic and Pharmacy
        • Principal Investigator:
          • Steven Powell, MD
        • Contact:
    • Tennessee
      • Nashville, Tennessee, United States, 37203
        • Recruiting
        • Tennessee Oncology - Nashville / Sarah Cannon Research Institute
        • Contact:
        • Principal Investigator:
          • Meredith McKean, MD, MPH
    • Texas
      • Houston, Texas, United States, 77030
        • Recruiting
        • The University of Texas MD Anderson Cancer Center
        • Contact:
        • Principal Investigator:
          • Funda Meric-Bernstam, MD
    • Utah
      • Cedar City, Utah, United States, 84720
        • Recruiting
        • Cedar City Hospital, SW Cancer Clinic, Sandra Maxwell Cancer Center
        • Principal Investigator:
          • Ramya Thota, MD
        • Contact:
        • Principal Investigator:
          • Derrick Haslem, MD
      • Saint George, Utah, United States, 84770
        • Recruiting
        • Dixie Regional Medical Center-River Road Campus
        • Principal Investigator:
          • Ramya Thota, MD
        • Contact:
        • Principal Investigator:
          • Derrick Haslem, MD
      • Salt Lake City, Utah, United States, 84107
        • Recruiting
        • Intermountain Healthcare
        • Contact:
        • Principal Investigator:
          • Ramya Thota, M.D.
        • Principal Investigator:
          • Derrick Haslem, M.D.
    • Virginia
      • Fairfax, Virginia, United States, 22042
        • Recruiting
        • Inova Schar Cancer Institute
        • Principal Investigator:
          • Timothy Cannon, MD
        • Contact:
    • Washington
      • Seattle, Washington, United States, 98104
        • Recruiting
        • Swedish Cancer Institute
        • Principal Investigator:
          • Philip Gold, MD
        • Contact:
    • Wisconsin
      • Burlington, Wisconsin, United States, 53105
        • Recruiting
        • Aurora Cancer Care - Burlington
        • Principal Investigator:
          • Antony Ruggeri, MD
        • Contact:
      • Germantown, Wisconsin, United States, 53022
        • Recruiting
        • Aurora Health Care - Germantown Health Center
        • Principal Investigator:
          • Antony Ruggeri, MD
        • Contact:
      • Grafton, Wisconsin, United States, 53024
        • Recruiting
        • Aurora Cancer Care - Grafton
        • Principal Investigator:
          • Antony Ruggeri, MD
        • Contact:
      • Green Bay, Wisconsin, United States, 54311
        • Recruiting
        • Aurora BayCare Medical Center
        • Principal Investigator:
          • Antony Ruggeri, MD
        • Contact:
      • Kenosha, Wisconsin, United States, 53142
        • Recruiting
        • Aurora Cancer Care - Kenosha South
        • Principal Investigator:
          • Antony Ruggeri, MD
        • Contact:
      • Marinette, Wisconsin, United States, 54143
        • Recruiting
        • Aurora Bay Area Medical Center
        • Principal Investigator:
          • Antony Ruggeri, MD
        • Contact:
      • Milwaukee, Wisconsin, United States, 53215
        • Recruiting
        • Aurora St. Luke's Medical Center
        • Principal Investigator:
          • Antony Ruggeri, MD
        • Contact:
      • Milwaukee, Wisconsin, United States, 53209
        • Recruiting
        • Aurora Cancer Care Milwaukee
        • Principal Investigator:
          • Antony Ruggeri, MD
        • Contact:
      • Milwaukee, Wisconsin, United States, 53223
        • Recruiting
        • Aurora Sinai Medical Center
        • Principal Investigator:
          • Antony Ruggeri, MD
        • Contact:
      • Milwaukee, Wisconsin, United States, 53227
        • Recruiting
        • Aurora West Allis Medical Center
        • Principal Investigator:
          • Antony Ruggeri, MD
        • Contact:
      • Oshkosh, Wisconsin, United States, 54904
        • Recruiting
        • Vince Lombardi Cancer Clinic - Oshkosh
        • Principal Investigator:
          • Antony Ruggeri, MD
        • Contact:
      • Racine, Wisconsin, United States, 53406
        • Recruiting
        • Aurora Cancer Care - Racine
        • Principal Investigator:
          • Antony Ruggeri, MD
        • Contact:
      • Sheboygan, Wisconsin, United States, 53081
        • Recruiting
        • Vince Lombardi Cancer Center
        • Principal Investigator:
          • Antony Ruggeri, MD
        • Contact:
      • Summit, Wisconsin, United States, 53066
        • Recruiting
        • Aurora Medical Center in Summit
        • Principal Investigator:
          • Antony Ruggeri, MD
        • Contact:
      • Two Rivers, Wisconsin, United States, 54241
        • Recruiting
        • Vince Lombardi Cancer Clinic - Two Rivers
        • Principal Investigator:
          • Antony Ruggeri, MD
        • Contact:
      • Wauwatosa, Wisconsin, United States, 53226
        • Recruiting
        • Aurora Cancer Care - Milwaukee West
        • Principal Investigator:
          • Antony Ruggeri, MD
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

12 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • 12 years of age or older (*Restrictions apply. Not all therapies are available for patients <18)
  • Histologically-proven locally advanced or metastatic solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma who is no longer benefiting from standard anti-cancer treatment or for whom, in the opinion of the treating physician, no such treatment is available or indicated
  • Performance status 0-2 (Per Eastern Cooperative Oncology Group (ECOG) criteria)

  • Patients must have acceptable organ function as defined below. However, as noted above, drug-specific inclusion/exclusion criteria specified in the protocol appendix for each agent will take precedence for this and all inclusion criteria:

    1. Absolute neutrophil count ≥ 1.5 x 106/µl
    2. Hemoglobin > 9.0 g/dl
    3. Platelets > 75,000/µl
    4. Total bilirubin < 2.0 mg/ dl, except in patients with Gilbert's Syndrome
    5. Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT) serum glutamic-pyruvic transaminase (SGPT) < 2.5 x institutional upper limit of normal (ULN) (or < 5 x ULN in patients with known hepatic metastases)
    6. Serum creatinine ≤ 1.5 × ULN or calculated or measured creatinine clearance ≥ 50 mL/min/1.73 m2
  • Patients must have disease that can be objectively measured by physical or radiographic exam (per RECIST v1.1 for solid tumor, Lugano criteria for non-Hodgkin lymphoma or International Myeloma Working Group criteria for multiple myeloma), defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥20 mm with conventional techniques or as ≥10 mm with spiral CT scan, MRI, or a subcutaneous or superficial lesion that can be measured with calipers by clinical exam. For lymph nodes, the short axis must be ≥15 mm. Patient's whose disease cannot be objectively measured by physical or radiographic examination (e.g., elevated serum tumor marker only, bone-only disease without an identifiable soft tissue component, or patients with only assessable non-measurable disease) are NOT eligible.
  • Results must be available from a genomic test or immunohistochemistry (IHC) test for protein expression performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified and College of American Pathologists (CAP)-accredited or New York State accredited (for labs offering services to residents of NY) laboratory. Labs that have registered the test with the NIH Genetic Testing Registry or that provide a report that has been designated as optimized for TAPUR participation are preferred, but not required. The genomic or IHC test used to qualify a patient for participation in TAPUR may have been performed on any specimen of the patient's tumor obtained at any point during the patient's care at the discretion of the patient's treating physician. Genomic assays performed on cell-free DNA in plasma ("liquid biopsies") will also be acceptable if the genomic analysis is performed in a laboratory that meets the criteria described above.
  • Ability to understand and the willingness to sign a written informed consent/assent document.
  • Have a tumor genomic profile for which single agent treatment with one of the FDA approved targeted anti-cancer drugs included in this study has potential clinical benefit based on the criteria described in protocol.
  • For orally administered drugs, the patient must be able to swallow and tolerate oral medication and must have no known malabsorption syndrome.
  • Because of the risks of drug treatment to the developing fetus, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and for four months following completion of study therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study or if she is the partner of a male participant in this study and becomes pregnant while he is participating in this study, she should inform her or her partner's treating physician immediately as well as her obstetrician. Female study patients who become pregnant must immediately discontinue treatment with any study therapy. Male patients should avoid impregnating a female partner. Male study patients, even if surgically sterilized, (i.e. post-vasectomy) must agree to one of the following: practice effective barrier contraception during the entire study treatment period and for a specified amount of time the last dose of study drug, or completely abstain from sexual intercourse.

Note: TAPUR does not explicitly exclude any type of solid tumor, but the patient must have measurable and evaluable disease per RECIST v1.1.

Exclusion Criteria:

  • Patients whose disease is not measurable or cannot be assessed by radiographic imaging or physical examination (e.g., elevated serum tumor marker only) are not eligible
  • Patients with primary brain tumors or leptomeningeal metastases are excluded.
  • Patients with previously treated brain metastases are eligible, provided that the patient has not experienced a seizure or had a clinically significant change in neurological status within the 3 months prior to registration. All patients with previously treated brain metastases must be clinically stable for at least 1 month after completion of treatment and off steroid treatment for one month prior to study enrollment.
  • Patients with known progressive brain metastases are eligible but additional eligibility criteria apply.

Note: there are additional exclusion criteria that may apply

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Group 5 (CSF1R,PDGFR,VEGFR)
Participants receive sunitinib - dosage, frequency and duration per label; acceptable genomic matches include CSF1R, PDGFR, VEGFR1/2/3, KIT, FLT-3, RET, FGFR1/2/3, VHL amplifications or mutations
Drug: Sunitinib
drug
Other Names:
  • Sutent
Other: Group 6 (mTOR, TSC)
Participants receive temsirolimus - dosage, frequency and duration per label; acceptable genomic matches include mTOR, TSC1/2, AKT1 mutations
Drug: Temsirolimus
drug
Other Names:
  • Torisel
Other: Group 8 (ERBB2)
Participants receive trastuzumab and pertuzumab - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression, and specific ERBB2 mutations
Drug: Trastuzumab and Pertuzumab
drug
Other Names:
  • Herceptin and Perjeta
Other: Group 9 (BRAF V600E/D/K/R)
Participants receive vemurafenib and cobimetinib - dosage, frequency and duration per label; acceptable genomic matches include BRAF V600E/D/K/R mutations
Drug: Vemurafenib and Cobimetinib
drug
Other Names:
  • Zelboraf and Cotellic
Other: Group 13 (RET,VEGFR1/2/3,KIT,PDGFRβ,RAF-1,BRAF)
Participants receive regorafenib - dosage, frequency and duration per label; acceptable genomic matches include RET, VEGFR1/2/3, KIT, PDGFRβ, RAF-1, BRAF mutations or amplifications
Drug: Regorafenib
drug
Other Names:
  • Stivarga
Other: Group 14 (BRCA1/2; ATM)
Participants receive olaparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic BRCA1/2 inactivating mutations; ATM mutations or deletions
Drug: Olaparib
drug
Other Names:
  • Lynparza
Other: Group 15 (POLE, POLD1)
Participants receive pembrolizumab - dosage, frequency and duration per label; acceptable genomic matches include specific POLE and POLD1 mutations
Drug: Pembrolizumab
drug
Other Names:
  • Keytruda
Other: Group 16 (MSI-H, high mutational load and others)
Participants receive nivolumab and ipilimumab - dosage, frequency and duration per label; acceptable genomic matches include MSI high status, high tumor mutational burden, MLH1, MSH2/6, PMS2, EPCAM mutations, specific POLE or POLD1 mutations, BRCA1/2, ATM, MSH3, PMS1, MLH3, EXO1, RFC1/2/3/4/5, PCNA, RPA1/2/3/4, and SSBP1 loss of function mutations
Drug: Nivolumab and Ipilimumab
drug
Other Names:
  • Opdivo and Yervoy
Other: Group 19 (BRCA1/2, PALB2)
Participants receive talazoparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic BRCA1/2 and PALB2 mutations
Drug: Talazoparib
drug
Other Names:
  • Talzenna
Other: Group 20 (ERBB2)
Participants receive atezolizumab plus PHESGO - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression
Drug: Atezolizumab and PHESGO
drug
Other Names:
  • Tecentriq and PHESGO
Other: Group 22 (ROS1 fusion)
Participants receive entrectinib - dosage, frequency and duration per label; acceptable genomic matches include any ROS1 fusion
Drug: Entrectinib
drug
Other Names:
  • Rozlytrek
Other: Group 23 (NTRK amplification)
Participants receive larotrectinib - dosage, frequency and duration per label; acceptable genomic matches include NTRK1/2/3 amplification
Drug: Larotrectinib
drug
Other Names:
  • Vitrakvi
Other: Group 24 (ERBB2)
Participants receive tucatinib plus trastuzumab SC - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression, and specific ERBB2 mutations
Drug: Tucatinib plus Trastuzumab Subcutaneous (SC)
drug
Other Names:
  • Tukysa and Herceptin Hylecta
Other: Group 4 (CDKN2A, CDK4, CDK6)
Participants receive palbociclib - dosage, frequency and duration per label; acceptable genomic matches include CDKN2A loss or mutation, CDK4, CDK6 amplifications, CDKN2B loss or mutation
Drug: Palbociclib
drug
Other Names:
  • Ibrance
Other: Group 17 (CDKN2A, CDK4, CDK6)
Participants receive abemaciclib - dosage, frequency and duration per label; acceptable genomic matches include CDKN2A loss or mutation, CDK4, CDK6 amplifications, CDKN2B loss or mutation
Drug: Abemaciclib
drug
Other Names:
  • Verzenio
Other: Group 21 (BRCA1/2, PALB2, ATM, and others)
Participants receive atezolizumab plus talazoparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic mutations in BRCA1/2, PALB2, ATM, ATR, CHEK2, FANCA, RAD51C, NBN, MLH1, MRE11A, CDK12; positive genomic instability score reported on the Myriad MyChoice CDx test; or Genomic Loss of Heterozygosity (LOH) Score above threshold as reported on a FoundationOne CDx test or another qualifying test for TAPUR with MTB approval
Drug: Atezolizumab and Talazoparib
drug
Other Names:
  • Tecentriq and Talzenna
Other: Group 25
Participants receive futibatinib- dosage, frequency and duration per label; acceptable genomic matches include FGFR 1,2,3,4 fusion (or other rearrangement) or mutation
Drug: Futibatinib
drug
Other Names:
  • Lytgobi

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Objective Response Rate defined as % of participants in a cohort with complete or partial response or with stable disease according to standard response criteria
Time Frame: Assessed at 16 weeks of treatment
Each cohort includes participants with the same tumor type, genomic variant and study drug. For solid tumors, the Response Evaluation Criteria for Solid Tumors (RECIST) criteria will be used, for non-Hodgkin Lymphoma, the Lugano Criteria will be used, and for multiple myeloma, the International Uniform Response Criteria for Multiple Myeloma will be used.
Assessed at 16 weeks of treatment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overall survival (OS)
Time Frame: Duration of survival from registration on study until death from any cause, assessed throughout end of study, up to 3 years
OS will be estimated using the Kaplan-Meier method
Duration of survival from registration on study until death from any cause, assessed throughout end of study, up to 3 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

American Society of Clinical Oncology

Collaborators

Bristol-Myers Squibb
Eli Lilly and Company
Bayer
Merck Sharp & Dohme LLC
Pfizer
AstraZeneca
Genentech, Inc.
Boehringer Ingelheim
Seagen Inc.
Taiho Oncology, Inc.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 14, 2016

Primary Completion (Estimated)

December 31, 2024

Study Completion (Estimated)

December 31, 2025

Study Registration Dates

First Submitted

February 11, 2016

First Submitted That Met QC Criteria

February 23, 2016

First Posted (Estimated)

February 26, 2016

Study Record Updates

Last Update Posted (Estimated)

April 26, 2024

Last Update Submitted That Met QC Criteria

April 25, 2024

Last Verified

January 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Pro00014171

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lymphoma, Non-Hodgkin

Clinical Trials on Palbociclib

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cyprus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe